Thales Partners with EVERING to Secure the Next-Generation of Wearable Fashion in Japan
Contactless payment technology brings convenience to consumers worldwide, especially in the wake of the current pandemic. And, by bringing contactless payment devices to wearables to integrate more seamlessly into users’ daily lives. Thales, with its strong history in providing secure payment products to banks and other financial institutions, now takes this to wearable fashion in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005664/en/
©EVERING
The EVERING, an NFC ring, enables contactless payments working on a “ Less is Smart” premise. The waterproof ceramic ring supports cash less and touch less payments, offering a seam less experience for users to pay when the ring is held in close proximity to the payment terminal. The waterproof battery- less ring requires no charging, and marries fashion with technology, with the convenience of contactless transactions.
Thales will provide both the secure embedded chip and Operating System as well as card personalisation services for the device, with EVERING as the Payment Card Issuer, enabling fast and secure contactless transactions on this ring. The payment data on the ring will be directly linked to customers’ prepaid bank accounts,. The payment personalisation services on the rings ensure optimal data management for EVERING. All integration and personalisation work on the rings will be undertaken by dedicated Thales teams in Asia, ensuring close collaboration with EVERING to meet the evolving needs of their end users.
“We are delighted to partner with EVERING, a company that is bridging technology and fashion with the launch of their contactless payment ring. Thales has a long history of providing digital identity and security solutions in Japan, notably in the area of mobile communications and banking services. This collaboration takes our commitment a step further as we work with an innovative start-up to support their customers in this fast-evolving payment ecosystem. With this partnership, Thales is accelerating our business development efforts with alternative payment issuers in Japan, including Fintech companies, as we continue to refine our technology for wearable devices,” Cyrille Dupont, Country Director, Thales in Japan
“Consumers in Japan acknowledge that contactless electronic transactions are the way forward, with rapid adoption accelerated by the pandemic. By combining aesthetics with functionality, and most importantly, security, the EVERING may well be a solution that can drive Japan towards becoming a cashless society. We decided to partner with Thales because of their proven track record in security and encryption technologies. With this partnership, we assure our customers that their financial transactions remain safe and secure and that the ring is equipped with international-standards of security technology,” Takeshi Kawada, Chief Executive Officer, EVERING
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
About Thales in Japan
Present in Japan since 1970, Thales works with over 500 partners ranging from large enterprises to SMEs. The Group serves Japanese needs in scientific, security and defence (Japanese government), aerospace, digital identity & security solutions (various Japanese organizations, MNOs, banks, governmental or civil markets), spatial, transportation and various industrial applications.
A strong portfolio of solutions and technologies enables Thales to meet customer and partner needs efficiently by supporting them in common projects. Key projects have enabled Thales in Japan to expand the business locally and to build a dynamic and skilled workforce.
With close to 150 employees in Japan, mainly in Tokyo, Thales’ ambition is to boost its local presence by partnering with strategic key industrial Japanese players and to address the needs of the local ecosystem.
About EVERING
Founded in February 2020 in Tokyo, EVERING is a high-technology company that strives to be truly smart, starting from payments to endless possibilities. The company adopts the philosophy of “ Simplicity in Design, Flawless Execution and Straightforward Functionality” in its products, thereby enabling an intuitive, seamless and refined user experience. By focusing only on the necessary elements in its products and coupling with a sleek design aesthetic, EVERING brings a new level of technology and design to Japan.
PLEASE VISIT
Digital Identity & Security
Download HD photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005664/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
Thales, Communications in Japan
Serene Koh
+65 6594 6898
serene.koh@asia.thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
